How much is too much? Outcomes in patients using high-dose insulin glargine

AACE Comprehensive Diabetes Management Algorithm 2013

(2015) Alan Garber et al.   Endocrine Practice

Clinical inertia, uncertainty and individualized guidelines

(2014) G. Reach   DIABETES & METABOLISM

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

(2014) Julio Rosenstock et al.   DIABETES CARE

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes

(2014) Silvio E. Inzucchi et al.   DIABETES CARE

Update on developments with SGLT2 inhibitors in the management of type 2 diabetes

(2014) Michael Nauck   Drug Design Development and Therapy

Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes

(2013) John B. Buse et al.   ANNALS OF INTERNAL MEDICINE

Clinical inertia in the treatment of hyperglycemia in type 2 diabetes patients in primary care

(2013) Manel Mata-Cases et al.   CURRENT MEDICAL RESEARCH AND OPINION

The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988-2010

(2013) S. Stark Casagrande et al.   DIABETES CARE

Clinical Inertia in People With Type 2 Diabetes: A retrospective cohort study of more than 80,000 people

(2013) K. Khunti et al.   DIABETES CARE

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin

(2013) Matthew C. Riddle et al.   DIABETES CARE

Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine

(2013) Matthew C. Riddle et al.   DIABETES CARE

Comparison of stepwise addition of prandial insulin to a basal-bolus regimen when basal insulin is insufficient for glycaemic control in type 2 diabetes: Results of the OSIRIS study

(2012) D. Raccah et al.   DIABETES & METABOLISM

Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)

(2012) Y. Seino et al.   DIABETES OBESITY & METABOLISM

Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial

(2012) Pablo Aschner et al.   LANCET

Contributions of Basal and Postprandial Hyperglycemia Over a Wide Range of A1C Levels Before and After Treatment Intensification in Type 2 Diabetes

(2011) M. Riddle et al.   DIABETES CARE

Telecare Provides Comparable Efficacy to Conventional Self-Monitored Blood Glucose in Patients with Type 2 Diabetes Titrating One Injection of Insulin Glulisine—the ELEONOR Study

(2011) Stefano Del Prato et al.   Diabetes Technology & Therapeutics

Comparison of 2 Intensification Regimens with Rapid-Acting Insulin Aspart in Type 2 Diabetes Mellitus Inadequately Controlled by Once-Daily Insulin Detemir and Oral Antidiabetes Drugs: The Step-Wise Randomized Study

(2011) Luigi Meneghini et al.   Endocrine Practice

A 24-Week, Randomized, Treat-to-Target Trial Comparing Initiation of Insulin Glargine Once-Daily With Insulin Detemir Twice-Daily in Patients With Type 2 Diabetes Inadequately Controlled on Oral Glucose-Lowering Drugs

(2010) S. G. Swinnen et al.   DIABETES CARE

Improved Glycemic Control with Insulin Glargine Versus Pioglitazone as Add-On Therapy to Sulfonylurea or Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus

(2010) Luigi Meneghini et al.   Endocrine Practice

Comparison between a basal-bolus and a premixed insulin regimen in individuals with type 2 diabetes-results of the GINGER study

(2009) A. Fritsche et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes

(2009) T. Vilsbøll et al.   DIABETES OBESITY & METABOLISM

Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study

(2008) J-F. Blicklé et al.   DIABETES OBESITY & METABOLISM

Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial

(2008) Reinhard G Bretzel et al.   LANCET